Your session is about to expire
← Back to Search
HMI-102 for Pyridoxine-Dependent Epilepsy (pheNIX Trial)
pheNIX Trial Summary
This trial is testing a new drug for PKU patients with PAH deficiency. The safety and effectiveness of the drug will be followed for one year.
- Pyridoxine-Dependent Epilepsy (PDE)
- Phenylketonuria
pheNIX Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.pheNIX Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the aggregate amount of individuals participating in this medical trial?
"Affirmative. Clinicaltrials.gov's records demonstrate that this clinical study, first published on June 10th 2019, is actively seeking participants. 28 individuals need to be recruited from 13 distinct medical locations."
Is this trial currently welcoming new participants?
"Affirmative. The clinicaltrials.gov registry states that this experiment is currently recruiting volunteers, with the initial posting dating back to June 10th 2019 and most recent update being October 8th 2021. Across 13 centres, 28 patients need to be recruited for the trial."
What qualifications must a prospective participant possess to be considered for enrollment in this medical research?
"This medical trial necessitates 28 phenylketonuria patients aged between 18 and 55. Additionally, applicants must be able to stay consistent with their diet regimen for the duration of the experiment (unless otherwise directed)."
Are individuals over the age of 70 being invited to join this research project?
"According to the qualifications listed, this clinical trial is open for individuals aged 18-55. Separately, there are 14 opportunities specifically tailored towards minors and 12 that cater towards senior citizens."
What goals are the researchers hoping to accomplish with this experiment?
"This clinical trial aims to measure the emergence of treatment-related adverse events between Week 24 and 28 as its primary outcome (Dose Escalation Phase). Secondary objectives include assessing incidences of plasma Phe concentration thresholds up to Week 28 post administration of HMI-102, recording changes in total protein intake at week 52 post administration of HMI-102, and tracking patients who reach plasma Phe concentrations at Week 52."
Are there numerous healthcare facilities conducting this experiment in the metropolitan area?
"The current enrolment of this clinical trial is taking place in 13 different cities, such as Chapel Hill, Philadelphia and Salt Lake City. To reduce travel costs and time, it may be beneficial to select the nearest site if you choose to participate."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger